Argonaut Therapeutics is assembling an international team of scientists and clinicians that strive to combat cancer through developing innovative and proprietary therapies. Argonaut Therapeutics has pioneered the development of inhibitors of protein arginine methyl-transferase (PRMT).
Argonaut’s most advanced product is a small molecule drug candidate which inhibits PRMT5 and activates pathways which lead to cancer cell death. A companion diagnostic is under development to enable a precision medicine approach to treating patients. Argonaut has a number of other early stage programmes underway.